INTENSITY THERAPEUTICS, INC.INTS

INTENSITY THERAPEUTICS, INC. Debt Disclosure

10-KFiled Mar 13, 20251 min read
Convertible Notes
Prior to the IPO, the Company entered into a series of interest-bearing convertible notes, which bore interest at rates ranging 3% to 10%, and were automatically converted upon the IPO at a discount ranging 30% to 35% to the conversion price of $11.50 per share, in accordance with the respective note agreements. Below is a summary of activity of convertibles notes for the year ended December 31, 2023 (in thousands):
PrincipalAccrued InterestTotal
As of January 1, 20234,250 99 4,349 
Issuance of Convertible Notes243 — 243 
Interest expense— 145 145 
Conversion to common stock upon IPO(4,493)(244)(4,737)
Balance as of December 31, 2023$— $— $— 
Upon the IPO, all convertible note principal and accrued interest of $4.5 million and $0.2 million, respectively, converted into an aggregate of 1,399,716 shares of common stock, pursuant to the conversion terms in each respective note. The Company recorded a non-operating loss on debt extinguishment of $2.3 million in the statement of operations, which is equal to the aggregate discounts on the IPO price specified in each convertible note agreement. In addition, upon the IPO, the remaining $0.2 million balance of unamortized discount on 2022 Convertible Notes was recognized and recorded in Interest Expense on the Statement of Operations.
Free Sentinel

Want the next INTENSITY THERAPEUTICS, INC. debt disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment INTENSITY THERAPEUTICS, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2024Mar 13, 2025Showing above
2023Mar 14, 2024

About Debt Disclosures

Debt disclosures detail a company's borrowing structure — the types of instruments, interest rates, maturity schedule, and covenant restrictions that define its financial obligations and flexibility. This section is essential for assessing refinancing risk, interest rate exposure, and the margin of safety against financial distress.

Key signals: the maturity schedule reveals concentration risk — large maturities within 1-2 years during tight credit markets can force dilutive refinancing or asset sales. Compare the fair value of debt against carrying amount to gauge whether the market views the company's credit risk differently than the balance sheet suggests. Watch covenant compliance disclosures for tightening cushions, especially leverage and interest coverage ratios. Variable-rate debt exposure quantifies sensitivity to interest rate changes. Secured versus unsecured mix affects recovery rates and future borrowing capacity. Compare net debt-to-EBITDA against industry peers and covenant limits to assess financial health.

Other Available Disclosures

Income TaxesLeasesSegmentsNew StandardsPay vs Performance